Kagawa Laboratory Tokai University School of Medicine

2020

1. Anzai K, Tsuruya K, Morimachi M, Arase Y, Hirose S, Hirabayashi K, Adachi Y, Kagawa T. The Impact of a Heterozygous SLCO1B3 Null Variant on the Indocyanine Green Retention Test. J Pharm Sci. 2020 Oct;109(10):3206-3209. doi: 10.1016/j.xphs.2020.06.020. PMID: 32593714

2. Kakizaki M, Yamamoto Y, Otsuka M, Kitamura K, Ito M, Kawai HD, Muramatsu M, Kagawa T, Kotani A. Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model. J Biol Chem. 2020 Aug 28;295(35):12449-12460. doi: 10.1074/jbc.RA120.014317. PMID: 32651230

3. Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel). 2020 Oct 22;12(11):3078. doi: 10.3390/cancers12113078. PMID: 33105621

4. Saito K, Kagawa T, Tsuji K, Kumagai Y, Sato K, Sakisaka S, Sakamoto N, Aiso M, Hirose S, Mori N, Tanaka R, Uraoka T, Takata K, Ogawa K, Mori K, Sato M, Nishiya T, Takamatsu K, Arakawa N, Izumi T, Ohno Y, Saito Y, Takikawa H. Plasma Lipid Profiling of Three Types of Drug-Induced Liver Injury in Japanese Patients: A Preliminary Study. Metabolites. 2020 Aug 31;10(9):355. doi: 10.3390/metabo10090355. PMID: 32878279

5. Hirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, Shiraishi K, Suzuki M, Ieda S, Kagawa T. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS One. 2020 Nov 13;15(11):e0241770. doi: 10.1371/journal.pone.0241770. eCollection 2020. PMID: 33186403

6. Mashiko T, Masuoka Y, Nakano A, Tsuruya K, Hirose S, Hirabayashi K, Kagawa T, Nakagohri T. Intussusception due to hematogenous metastasis of hepatocellular carcinoma to the small intestine: A case report. World J Gastroenterol. 2020 Nov 14;26(42):6698-6705. doi: 10.3748/wjg.v26.i42.6698. PMID: 33268957

7. Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol. 2020 Oct;55(10):977-989. doi: 10.1007/s00535-020-01707-6. PMID: 32666202

8. Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020. PMID: 33061517

9. Nakano Y, Kamiya A, Sumiyoshi H, Tsuruya K, Kagawa T, Inagaki Y. A Deactivation Factor of Fibrogenic Hepatic Stellate Cells Induces Regression of Liver Fibrosis in Mice. Hepatology. 2020 Apr;71(4):1437-1452. doi: 10.1002/hep.30965. PMID: 31549421.

10. Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H, Tanaka Y, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Terai S, Koizumi W. Usefulness of autotaxin for the complications of liver cirrhosis. World J Gastroenterol. 2020 Jan 7;26(1):97-108. doi: 10.3748/wjg.v26.i1.97. PMID: 31933517; PMCID: PMC6952300.

11. Arase Y, Tsuruya K, Hirose S, Ogiwara N, Yokota M, Anzai K, Deguchi R, Shiraishi K, Shirai T, Kagawa T. Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases. Hepatology. 2020 Feb;71(2):757-759. doi: 10.1002/hep.30904. PMID: 31429969; PMCID: PMC7028030.

12. Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2020 Jan 26;12(2):293. doi: 10.3390/cancers12020293. PMID: 31991869; PMCID: PMC7073176.

13. Yamamoto Y, Kakizaki M, Shimizu T, Carreras J, Chiba T, Chamoto K, Kagawa T, Aoki T, Nakamura N, Ando K, Kotani A. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. Int Immunol. 2020 Jul 28;32(8):519-531. doi: 10.1093/intimm/dxaa018. PMID: 32219331.

14. Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto M, Kagawa T, Tanaka K, Kako M, Koizumi W. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer. 2020 Apr;9(2):193-206. doi: 10.1159/000504604. PMID: 32399433; PMCID: PMC7206580.

​

2019

1. Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig. 2019 Jul;39(7):631-641. doi: 10.1007/s40261-019-00785-6. PMID: 30993553; PMCID: PMC6593121.

2. Tamori A, Inoue K, Kagawa T, Takaguchi K, Nouso K, Iwasaki Y, Minami M, Hai H, Enomoto M, Kawada N. Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. Hepatol Res. 2019 Dec;49(12):1365-1373. doi: 10.1111/hepr.13410. PMID: 31323165.

3. Hirose S, Yamaji Y, Tsuruya K, Ogawa Y, Miyaoka M, Kagawa T. Rapid Regression of B-Cell Non-Hodgkin's Lymphoma after Eradication of Hepatitis C Virus by Direct Antiviral Agents. Case Rep Gastroenterol. 2019 Jul 26;13(2):336-341. doi: 10.1159/000501546. PMID: 31543755; PMCID: PMC6738223.

4. Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res. 2019 Jan;49(1):105-110. doi: 10.1111/hepr.13288. PMID: 30565816.

5. Tsuruya K, Koizumi J, Sekiguchi T, Hara T, Sekiguchi Y, Anzai K, Arase Y, Hirose S, Kagawa T. Successful Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices Using Foam Sclerosant Followed by Glue Embolization of Gastrorenal Shunt via the Brachial Vein Approach in a Severely Obese Patient. Ann Vasc Dis. 2019 Dec 25;12(4):562-565. doi: 10.3400/avd.cr.19-00084. PMID: 31942222; PMCID: PMC6957899.

6. Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clin Drug Investig. 2019 Jan;39(1):45-54. doi: 10.1007/s40261-018-0714-5. PMID: 30284699; PMCID: PMC6510826.

 

2018

1. Kakizaki M, Yamamoto Y, Yabuta S, Kurosaki N, Kagawa T, Kotani A. The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes. PLoS One. 2018 Dec 31;13(12):e0205886. doi: 10.1371/journal.pone.0205886. PMID: 30596665; PMCID: PMC6312312.

2. Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271. PMID: 30581275; PMCID: PMC6295839.

3. Kamiya A, Chikada H, Ida K, Ando E, Tsuruya K, Kagawa T, Inagaki Y. An in vitro model of polycystic liver disease using genome-edited human inducible pluripotent stem cells. Stem Cell Res. 2018 Oct;32:17-24. doi: 10.1016/j.scr.2018.08.018. PMID: 30172093.

4. Fujii Y, Koizumi J, Hara T, Sekiguchi T, Ono S, Mine T, Kagawa T, Hirose S, Tsuruya K, Anzai K, d'Othee BJ, Imai Y. Utility of a 3D Roadmap During Balloon- occluded Retrograde Transvenous Obliteration for Gastric Varices. Tokai J Exp Clin Med. 2018 Apr 20;43(1):14-18. PMID: 29637534.

5. Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg- interferon sequential therapy. J Gastroenterol. 2018 Feb;53(2):247-257. doi: 10.1007/s00535-017-1360-z. PMID: 28634723.

 

2017

1. Kagawa T, Adachi Y, Hashimoto N, Mitsui H, Ohashi T, Yoneda M, Hasegawa I, Hirose S, Tsuruya K, Anzai K, Mine T. Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms. Hepatology. 2017 Mar;65(3):1065-1068. doi: 10.1002/hep.28950. PMID: 27863442; PMCID: PMC5324621.

 

2016

1. Anzai K, Chikada H, Tsuruya K, Ida K, Kagawa T, Inagaki Y, Mine T, Kamiya A. Foetal hepatic progenitor cells assume a cholangiocytic cell phenotype during two-dimensional pre-culture. Sci Rep. 2016 Jun 23;6:28283. doi: 10.1038/srep28283. PMID: 27335264; PMCID: PMC4917868.

2. Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol. 2016 Mar 17;16:38. doi: 10.1186/s12876-016-0454-z. PMID: 26987437; PMCID: PMC4794926.

3. Shomura M, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, Tsuruya K, Takahira S, Mine T. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer. 2016 Nov 11;16(1):878. doi: 10.1186/s12885-016-2908-7. PMID: 27835949; PMCID: PMC5106792.

 

2015

1. Kagawa T, Hirose S, Arase Y, Oka A, Anzai K, Tsuruya K, Shiraishi K, Orii R, Ieda S, Nakazawa T, Tomita K, Hokari R, Miura S, Ebinuma H, Saito H, Kitamura T, Horie Y, Okuse C, Wasada M, Inoko H, Tohkin M, Saito Y, Maekawa K, Takikawa H, Mine T. No contribution of the ABCB11 p.444A polymorphism in Japanese patients with drug-induced cholestasis. Drug Metab Dispos. 2015 May;43(5):691-7. doi: 10.1124/dmd.114.061325. PMID: 25713208.

2. Kagawa T, Oka A, Kobayashi Y, Hiasa Y, Kitamura T, Sakugawa H, Adachi Y, Anzai K, Tsuruya K, Arase Y, Hirose S, Shiraishi K, Shiina T, Sato T, Wang T, Tanaka M, Hayashi H, Kawabe N, Robinson PN, Zemojtel T, Mine T. Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype. Hum Mutat. 2015 Mar;36(3):327-32. doi: 10.1002/humu.22745. PMID: 25546334.

3. Itou C, Koizumi J, Hashimoto T, Myojin K, Kagawa T, Mine T, Imai Y. Balloon- Occluded Retrograde Transvenous Obliteration for the Treatment of Gastric Varices: Polidocanol Foam Versus Liquid Ethanolamine Oleate. AJR Am J Roentgenol. 2015 Sep;205(3):659-66. doi: 10.2214/AJR.14.13389. PMID: 26295655.

4. Tsuruya K, Chikada H, Ida K, Anzai K, Kagawa T, Inagaki Y, Mine T, Kamiya A. A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells. Stem Cells Dev. 2015 Jul 15;24(14):1691-702. doi: 10.1089/scd.2014.0479. PMID: 25808356; PMCID: PMC4499795.

 

2014

1. Itou C, Koizumi J, Hashimoto T, Myojin K, Kagawa T, Mine T, Imai Y. Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report. Cardiovasc Intervent Radiol. 2014 Jun;37(3):800-4. doi: 10.1007/s00270-013-0761-5. PMID: 24170168; PMCID: PMC4024151.

2. Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014 Sep 27;6(9):670-6. doi: 10.4254/wjh.v6.i9.670. PMID: 25276283; PMCID: PMC4179146.

3. Kagawa T, Orii R, Hirose S, Arase Y, Shiraishi K, Mizutani A, Tsukamoto H, Mine T. Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells. J Gastroenterol. 2014 May;49(5):890-9. doi: 10.1007/s00535-013-0833-y. PMID: 23722250.

 

2013

1. Koizumi J, Itou C, Wray R, Myojin K, Hashimoto T, Nagata Y, Yamamuro H, Tsuji T, Ichikawa T, Shiraishi K, Kagawa T, Mine T, Watanabe N, Matsumae M, Janne d'Othée B. Partial splenic embolisation using n-butyl cyanoacrylate: intraprocedural evaluation by magnetic resonance imaging. Eur Radiol. 2013 May;23(5):1429-42. doi: 10.1007/s00330-012-2711-z. PMID: 23160664.

2. Kojima S, Watanabe N, Takashimizu S, Kagawa T, Shiraishi K, Koizumi J, Hirabayashi K, Ohkubo T, Kamiguchi H, Tsuda M, Mine T. Senescent case of cholesterol ester storage disease that progressed to liver cirrhosis with a novel mutation (N250H) of lysosomal acid lipase gene. Hepatol Res. 2013 Dec;43(12):1361-7. doi: 10.1111/hepr.12087. PMID: 23675960.

3. Kagawa T, Kojima S, Shiraishi K, Hirose S, Arase Y, Takashimizu S, Watanabe N, Nagata N, Numata M, Shiozawa H, Nishizaki Y, Toki M, Sugita T, Nomura K, Sakaguchi T, Atsukawa K, Tajima H, Tei Y, Inomoto T, Mine T. Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. Hepatol Res. 2013 Sep;43(9):925-32. doi: 10.1111/hepr.12046. PMID: 23356876.

 

2012

1. Koizumi J, Hashimoto T, Myojin K, Itou C, Kagawa T, Nishibe T, Janne d'Othée B. Balloon-occluded retrograde transvenous obliteration of gastric varices: use of CT-guided foam sclerotherapy to optimize technique. AJR Am J Roentgenol. 2012 Jul;199(1):200-7. doi: 10.2214/AJR.11.7002. PMID: 22733913.

2. Koizumi J, Hashimoto T, Myojin K, Itou C, Hara T, Sekiguchi T, Ichikawa T, Imai Y, Kagawa T, Nagata N, Watanabe N, Mine T, Nishibe T, Saguchi T, Janne d'Othée B. Carbon dioxide (CO2) vs iodinated contrast digital subtraction angiography during balloon-occluded retrograde transvenous obliteration (BRTO) using foam sclerosant for gastric varices. J Vasc Interv Radiol. 2012 Nov;23(11):1453-1459.e1. doi: 10.1016/j.jvir.2012.08.004. PMID: 23101917.

3. Miyata M, Hata T, Yamakawa H, Kagawa T, Yoshinari K, Yamazoe Y. Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):41-7. doi: 10.1016/j.jsbmb.2012.04.008. PMID: 22561792.

4. Mizukami H, Kagawa T, Arase Y, Nakahara F, Tsuruya K, Anzai K, Hirose S, Shiraishi K, Shomura M, Koizumi J, Tobita K, Mine T. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2012 May;5(2):380-4. doi: 10.1159/000341259. PMID: 23525021; PMCID: PMC3409511.

5. Kagawa T, Kojima S, Shiraishi K, Takashimizu S, Nagata N, Shiozawa H, Nishizaki Y, Ikeda A, Tei Y, Atsukawa K, Kamochi J, Wasada M, Numata M, Arase Y, Hirose S, Yamada T, Hata Y, Watanabe N, Morizane T, Mine T. Weight-based high- and low-dose ribavirin in combination with peginterferon α-2b therapy for genotype 2 chronic hepatitis C: A randomized trial. Hepatol Res. 2012 Apr;42(4):351-8. doi: 10.1111/j.1872-034X.2011.00944.x. PMID: 22176474.

6. Hirose S, Kagawa T, Shiraishi K, Nagata N, Okada K, Tajima T, Mukai M, Sekido Y, Mine T. Type 1 gastric cancer presenting as protein-losing gastroenteropathy and ball-valve syndrome. Dig Endosc. 2012 Jan;24(1):55. doi: 10.1111/j.1443-1661.2011.01164.x. PMID: 22211419.

 

2011

1. Takashimizu S, Kojima SI, Nagata J, Nishizaki Y, Kagawa T, Shiraishi K, Mine T, Kaneko JI, Kokudo N, Watanabe N. Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C. Clin J Gastroenterol. 2011 Jun;4(3):167-173. doi: 10.1007/s12328-011-0216-y. PMID: 26189349.

2. Takashimizu S, Kojima S, Nishizaki Y, Kagawa T, Shiraishi K, Mine T, Watanabe N. Effect of endothelin A receptor antagonist on hepatic hemodynamics in cirrhotic rats. Implications for endothelin-1 in portal hypertension. Tokai J Exp Clin Med. 2011 Jul 20;36(2):37-43. PMID: 21769771.

 

2010

1. Koizumi J, Hashimoto T, Myojin K, Fukushima T, Ichikawa T, Kagawa T, Kojima S, Watanabe N, Mine T, Nishibe T, Janne d'Othée B. C-arm CT-guided foam sclerotherapy for the treatment of gastric varices. J Vasc Interv Radiol. 2010 Oct;21(10):1583-7. doi: 10.1016/j.jvir.2010.05.029. PMID: 20801674.

2. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T; Tokai RFA Study Group. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010 Aug 1;116(15):3638-44. doi: 10.1002/cncr.25142. PMID: 20564097.

3. Numata M, Kagawa T, Kojima S, Hirose S, Nagata N, Shiraishi K, Watanabe N, Shiozawa H, Nishizaki Y, Motegi S, Takashimizu S, Kamochi J, Wasada M, Ohno T, Tei Y, Nakano A, Yamada T, Atsukawa K, Watanabe T, Mine T. Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. Hepat Res Treat. 2010;2010:702748. doi: 10.1155/2010/702748. PMID: 21188199; PMCID: PMC3003990.

 

2008

1. Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, Tanaka H, Arias IM, Mine T. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G58-67. doi: 10.1152/ajpgi.00367.2007. PMID: 17947449.

2. Kagawa T, Shiozawa H, Kojima S, Takashimizu S, Nagata N, Numata M, Morino F, Nishizaki Y, Mochizuki K, Watanabe N, Watanabe T, Matsuzaki S, Mine T. Eight- week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C. Hepatol Res. 2008 Mar;38(3):259-66. doi: 10.1111/j.1872-034X.2007.00260.x. PMID: 17825059.

 

2007

1. Watanabe N, Kojima S, Takashimizu S, Nishizaki Y, Kagawa T, Phillips MJ. Initial site of bile regurgitation following extrahepatic biliary obstruction in living rats. J Gastroenterol Hepatol. 2007 Nov;22(11):1983-92. doi: 10.1111/j.1440-1746.2006.04623.x. PMID: 17914981.

2. Watanabe N, Takashimizu S, Nishizaki Y, Kojima S, Kagawa T, Matsuzaki S. An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation. J Gastroenterol. 2007 Sep;42(9):775-82. doi: 10.1007/s00535-007-2093-1. PMID: 17876548.

3. Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, Tanaka H, Arias IM, Mine T. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G58-67. doi: 10.1152/ajpgi.00367.2007. PMID: 17947449.

4. Mochizuki K, Kagawa T, Numari A, Harris MJ, Itoh J, Watanabe N, Mine T, Arias IM. Two N-linked glycans are required to maintain the transport activity of the bile salt export pump (ABCB11) in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G818-28. doi: 10.1152/ajpgi.00415.2006. PMID: 17082223.

5. Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T. Altered cell motility behaviour and reorganization of contractile proteins after primary monolayer cultures of isolated hepatocytes. Tokai J Exp Clin Med. 2007 Mar 20;32(1):34-41. PMID: 21319055.

6. Takashimizu S, Watanabe N, Kojima S, Kagawa T, Mine T, Myojin K, Koizumi J. Efficacy of balloon-occluded retrograde transvenous obliteration (B-RTO) performed in a patient with primary biliary cirrhosis with severe recurrent hepatic encephalopathy due to splenorenal shunt. Tokai J Exp Clin Med. 2007 Jul 20;32(2):70-4. PMID: 21319062.

7. Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T, Matsuzaki S. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol Res. 2007 Aug;37(8):598-607. doi: 10.1111/j.1872-034X.2007.00115.x. PMID: 17517076.

​

2006

1. Watanabe N, Kagawa T, Kojima S, Takashimizu S, Nagata N, Nishizaki Y, Mine T. Taurolithocholate impairs bile canalicular motility and canalicular bile secretion in isolated rat hepatocyte couplets. World J Gastroenterol. 2006 Sep 7;12(33):5320-5. doi: 10.3748/wjg.v12.i33.5320. PMID: 16981261; PMCID: PMC4088198.

2. Watanabe N, Takashimizu S, Shiraishi K, Kagawa T, Nishizaki Y, Mine T, Akatsuka A, Selmi C, Gershwin ME. Primary biliary cirrhosis with multinucleated hepatocellular giant cells: implications for pathogenesis of primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2006 Sep;18(9):1023-7. doi: 10.1097/01.meg.0000230082.60921.be. PMID: 16894319.

3. Takahashi H, Kagawa T, Kobayashi K, Hirabayashi H, Yui M, Begum L, Mine T, Takagi S, Saheki T, Shinohara Y. A case of adult-onset type II citrullinemia-- deterioration of clinical course after infusion of hyperosmotic and high sugar solutions. Med Sci Monit. 2006 Feb;12(2):CS13-5. PMID: 16449956.

4. Nishizaki Y, Morizane T, Kojima S, Sakuma K, Koyama A, Shiozawa H, Morino F, Aoki J, Matsuzaki S, Kagawa T, Watanabe N, Mine T. Predictive factors for the response to lamivudine in HBV-infected patients with chronic hepatitis and cirrhosis. Tokai J Exp Clin Med. 2006 Sep 20;31(3):121-4. PMID: 21302238.

5. Watanabe N, Nishizaki Y, Kojima S, Takashimizu S, Nagata N, Kagawa T, Shiraishi K, Mine T, Matsuzaki S. Clinical significance of serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic liver disease. Tokai J Exp Clin Med. 2006 Sep 20;31(3):96-101. PMID: 21302232.

 

2004

1. Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol. 2004 Jun 1;10(11):1686-7. doi: 10.3748/wjg.v10.i11.1686. PMID: 15162553; PMCID: PMC4572782.

2. Harris MJ, Kagawa T, Dawson PA, Arias IM. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells. J Gastroenterol Hepatol. 2004 Jul;19(7):819-25. doi: 10.1111/j.1440-1746.2004.03347.x. PMID: 15209631.

3. Mochizuki K, Kagawa T, Takashimizu S, Kawazoe K, Kojima S, Nagata N, Nakano A, Nishizaki Y, Shiraishi K, Itakura M, Watanabe N, Mine T, Matsuzaki S. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol. 2004 Mar 1;10(5):733-6. doi: 10.3748/wjg.v10.i5.733. PMID: 14991949; PMCID: PMC4716920.

 

2002

1. Kagawa T, Varticovski L, Sai Y, Arias IM. Mechanism by which cAMP activates PI3-kinase and increases bile acid secretion in WIF-B9 cells. Am J Physiol Cell Physiol. 2002 Dec;283(6):C1655-66. doi: 10.1152/ajpcell.00041.2002. PMID: 12388099.

​

2000

1. Hosoi K, Hagihara M, Kagawa T, Watanabe N, Matsuzaki S. The serum soluble HLA-DR antigens as a predictive marker of the response to interferon-alpha treatment in patients with chronic hepatitis C. Tokai J Exp Clin Med. 2000 Oct;25(3):117-24. PMID: 11368209.

 

1999

1. Kagawa T, Sato M, Hosoi K, Uchiyama J, Nishizaki Y, Watanabe N, Inagaki Y, Kimura M, Matsuzaki S. Absence of R1066X mutation in six Japanese patients with Dubin-Johnson syndrome. Biochem Mol Biol Int. 1999 Apr;47(4):639-44. doi: 10.1080/15216549900201693. PMID: 10319416.

2. Hagihara M, Hosoi K, Kagawa T, Gansuvd B, Munkhbat B, Shimura T, Watanabe N, Matsuzaki S, Tsuji K. Serum soluble HLA-DR antigens in autoimmune hepatitis. Autoimmunity. 1999 Oct;31(2):85-93. doi: 10.3109/08916939908994051. PMID: 10680746.

 

1998

1. Kagawa T, Watanabe N, Sato M, Nakano A, Nishizaki Y, Hosoi K, Takashimizu S, Uchiyama J, Kimura M, Matsuzaki S. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats. Biochem Mol Biol Int. 1998 Mar;44(3):443-52. doi: 10.1080/15216549800201462. PMID: 9556204.

2. Kagawa T, Hosoi K, Takashimizu S, Kawazoe K, Mochizuki K, Wasada M, Nagata N, Uchiyama J, Nakano A, Nishizaki Y, Watanabe N, Matsuzaki S. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. Am J Gastroenterol. 1998 Feb;93(2):192-6. doi: 10.1111/j.1572-0241.1998.00192.x. PMID: 9468240.

 

1997

1. Hagihara M, Shimura T, Takebe K, Munkhbat B, Hosoi K, Kagawa T, Watanabe N, Matsuzaki S, Yamamoto K, Sato K, Tsuji K. Serum concentrations of soluble HLA- class I and CD8 forms in patients with viral hepatic disorders. J Gastroenterol. 1997 Jun;32(3):338-43. doi: 10.1007/BF02934490. PMID: 9213247.